Today

Agents

Chat

Arena

Discover

More

App

AIM ImmunoTech CEO Thomas K Equels acquires common shares worth $4,992

AIM•2026-09-18

CEO buys additional AIM ImmunoTech shares

Thomas K. Equels, CEO, president and director, bought 24,000 AIM ImmunoTech common shares at $0.21 each.

Direct holdings rose to following the purchase.

126,822 shares

Related News

Waste Connections, Inc. <WCN.N>: UBS raises to Buy from Neutral; raises target price to $200 from $176

WCN•2026-09-18

Nucor declares quarterly cash dividend of $0.56 a share

NUE•2026-09-18

Silicon Valley Acquisition Corp. deal partner EigenQ secures USD 45 million convertible note financing

Sources

S

AIM ImmunoTech CEO Thomas K Equels acquires common shares worth $4,992

Sec

SVAQ

•

2026-09-18

Armstrong Tectum acoustic panels feature in Boys & Girls Club of Washington County facility build in Maryland

AWI•2026-09-18

Sagtec Global prices US$552,500 private placement to Pahang prince at US$0.65/share

SAGT•2026-09-18

AIM ImmunoTech CEO Thomas K Equels acquires common shares worth $4,992 - AIM News | Rallies